Holen Sie sich die Stockscreener-App
8.84
1.34%
-0.12
Handel nachbörslich:
8.93
0.09
+1.02%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$8.96
Offen:
$8.95
24-Stunden-Volumen:
11.70M
Relative Volume:
0.96
Marktkapitalisierung:
$11.10B
Einnahmen:
$15.05B
Nettoeinkommen (Verlust:
$-883.30M
KGV:
-11.95
EPS:
-0.74
Netto-Cashflow:
$1.89B
1W Leistung:
-6.36%
1M Leistung:
-7.24%
6M Leistung:
-23.46%
1J Leistung:
-25.27%
1-Tages-Spanne:
$8.75
$8.955
1-Wochen-Bereich:
$8.75
$9.37
52-Wochen-Spanne:
$8.75
$13.55
Viatris Inc Stock (VTRS) Company Profile
Firmenname
Viatris Inc
Sektor
Telefon
(724) 514-1465
Adresse
1000 MYLAN BOULEVARD, CANONSBURG
Vergleichen Sie VTRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
8.84 | 11.10B | 15.05B | -883.30M | 1.89B | -0.74 |
|
ZTS
Zoetis Inc
|
165.02 | 73.07B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.14 | 47.43B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.12 | 45.72B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.49 | 17.75B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.75 | 14.03B | 612.78M | -86.37M | -62.91M | -0.87 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-19 | Fortgesetzt | Jefferies | Buy |
| 2023-10-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-10 | Hochstufung | UBS | Sell → Neutral |
| 2022-11-08 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Fortgesetzt | Jefferies | Hold |
| 2022-06-14 | Eingeleitet | UBS | Sell |
| 2022-05-10 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Eingeleitet | Citigroup | Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-03-08 | Herabstufung | Goldman | Buy → Neutral |
| 2021-03-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Eingeleitet | Argus | Hold |
| 2020-12-14 | Eingeleitet | Bernstein | Mkt Perform |
Alle ansehen
Viatris Inc Aktie (VTRS) Neueste Nachrichten
Viatris Inc. Announcement: If You Have Suffered Losses in Viatris Inc. (NASDAQ: VTRS), You Are - Bluefield Daily Telegraph
The Global Market for Paclitaxel Injections Presents an - GlobeNewswire
Why Pfizer Is My Largest Healthcare Position - The Motley Fool
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris – VTRS - TradingView
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Viatris Inc. (VTRS) Faces Investor Scrutiny After Possible - GlobeNewswire
Viatris Inc. (VTRS) Faces Investor Scrutiny After Possible Disclosure Delay About June 2024 FDA Inspection of Manufacturing Facility – Hagens Berman - TradingView
Is Viatris Inc. (NASDAQ:VTRS) One of The Best Stocks to Buy According to Billionaire David Einhorn? - Insider Monkey
VTRS Investor News: Rosen Law Firm Encourages Viatris Inc. Investors to Inquire About Securities Class Action InvestigationVTRS - PR Newswire
Viatris Inc. Announcement: If You Have Suffered Losses in - GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris - GlobeNewswire
Viatris Inc. Being Investigated on Behalf of Viatris Inc. Investors. Contact Levi & Korsinsky For Details. - ACCESS Newswire
VTRS Stock Quote - richtv.io
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Viatris Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Viatris Inc. (VTRS) - ACCESS Newswire
Did Viatris Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky InvestigateVTRS - ACCESS Newswire
VTRS Investigation: Rosen Law Firm Encourages Viatris Inc. Investors to Inquire About Securities Class Action InvestigationVTRS - PR Newswire
Viatris Inc. Announces Quarterly Dividend, Payable on March 18, 2025 -February 27, 2025 at 06:30 am EST - Marketscreener.com
Is Viatris Inc. (VTRS) the Best Nasdaq Stock Under $20 to Buy Now? - MSN
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris - StreetInsider.com
Opus, Viatris Unit Sue Sandoz to Block Copy of Ryzumvi Eye Drug - Bloomberg Law
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc.VTRS - PR Newswire
Viatris Inc. Under Investor Scrutiny: Levi & Korsinsky Launches Securities Investigation - Apna Kal
Viatris Stock Plummets Over 15% Amid Earnings Miss and FDA Warning – Investors Encouraged to Take Action - Apna Kal
Rosen Law Firm Encourages Viatris Inc. Investors to Inquire About Securities Class Action Investigation – VTRS - Bluefield Daily Telegraph
Viatris Inc (VTRS) Volatility Hits 3.27% – Here Is What You Should Do - Stocks Register
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Viatris Inc. (VTRS) And Encourages Shareholders to Reach Out - Markets Insider
Investors who Lost Money on Viatris Inc. Should Contact Levi & Korsinsky About an Ongoing InvestigationVTRS - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Viatris Inc. (VTRS) and Encourages Shareholders to Learn More About the Investigation - Markets Insider
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris - PR Newswire
Viatris Inc. (VTRS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Markets Insider
Viatris Inc. (VTRS) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - Business Wire
Viatris’s SWOT analysis: generic drug maker’s stock faces headwinds - Investing.com
Viatris’s SWOT analysis: generic drug maker’s stock faces headwinds By Investing.com - Investing.com UK
Viatris Inc. (VTRS) Shareholders May Have Been Affected by FraudLevi & Korsinsky Investigates - ACCESS Newswire
Viatris at Barclays Conference: Strategic Moves Amid Challenges - Investing.com
Securities Fraud Investigation Into Viatris Inc. (VTRS) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Business Wire
Shareholder Rights Advocates at Levi & Korsinsky Investigate Viatris Inc. (VTRS) Regarding Possible Securities Fraud Violations - ACCESS Newswire
ATTENTION Viatris Inc. Investors: You May Have Been Affected by FraudContact Levi & Korsinsky to Discuss Your Rights - ACCESS Newswire
Viatris Inc. (VTRS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Why Viatris Inc. (VTRS) Is Plunging So Far In 2025 - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Viatris Inc. (VTRS) And Encourages Investors to Connect - Markets Insider
Viatris price target lowered to $13 from $15 at Jefferies - MSN
Finanzdaten der Viatris Inc-Aktie (VTRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
0.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):